GuidelineAntimicrobial resistance and infection control2025
Dutch guideline for the prevention and control of multidrug-resistant organisms in the hospital setting, 2024 update.
Guideline in Antimicrobial resistance and infection control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Carbapenem-Resistant Enterobacterales (CRE) in Europe: Surveillance Challenges, Emerging Threats and Public Health Preparedness.Antibiotics (Basel, Switzerland) · 2026Review
- Development and internal-external validation of a machine learning-based risk prediction model for multidrug resistance in mechanically ventilated ICU patients with chronic obstructive pulmonary disease.Frontiers in medicine · 2026Article
- Tackling a global threat: a clinical scenario-based framework for preventing and managingFrontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of multidrug-resistant organisms (MDROs) represents a significant challenge for global healthcare systems. The Netherlands maintains one of the lowest antimicrobial resistance rates in the world, attributed to prudent antibiotic use and effective infection prevention and control policies in healthcare settings. This report presents an updated national guideline for the infection prevention and control of MDROs in hospitals, developed by the Dutch Collaborative Partnership for Infection Prevention Guidelines (SRI). Using a multidisciplinary approach and evidence-based frameworks such as AGREE-II and GRADE, the guideline addresses the definition of MDRO, risk assessment and recommendations for MDRO screening, isolation and infection prevention measures, source and contact tracing, discontinuation of isolation measures, and organization of care. It incorporates new evidence, and other aspects such as patient perspectives, sustainability, costs, and organizational factors, providing practical recommendations to mitigate MDRO transmission. This update aims to strengthen national infection control practices and sustain the Dutch low antimicrobial resistance levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.